108 related articles for article (PubMed ID: 33249403)
1. Accuracy and inter-reader agreement of breast MRI for cancer staging using 0.08 mmol/kg of gadobutrol.
Cozzi A; Buragina G; Spinelli D; Schiaffino S; Zanardo M; Di Leo G; Carbonaro LA; Sardanelli F
Clin Imaging; 2021 Apr; 72():154-161. PubMed ID: 33249403
[TBL] [Abstract][Full Text] [Related]
2. Preliminary study: Breast cancers can be well seen on 3T breast MRI with a half-dose of gadobutrol.
Melsaether AN; Kim E; Mema E; Babb J; Kim SG
Clin Imaging; 2019; 58():84-89. PubMed ID: 31279989
[TBL] [Abstract][Full Text] [Related]
3. Comparison of gadoteric acid and gadobutrol for detection as well as morphologic and dynamic characterization of lesions on breast dynamic contrast-enhanced magnetic resonance imaging.
Renz DM; Durmus T; Böttcher J; Taupitz M; Diekmann F; Huppertz A; Pfeil A; Maurer MH; Streitparth F; Bick U; Hamm B; Fallenberg EM
Invest Radiol; 2014 Jul; 49(7):474-84. PubMed ID: 24637587
[TBL] [Abstract][Full Text] [Related]
4. Is there a systematic bias of apparent diffusion coefficient (ADC) measurements of the breast if measured on different workstations? An inter- and intra-reader agreement study.
Clauser P; Marcon M; Maieron M; Zuiani C; Bazzocchi M; Baltzer PA
Eur Radiol; 2016 Jul; 26(7):2291-6. PubMed ID: 26443604
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI.
Kuhl C; Csőszi T; Piskorski W; Miszalski T; Lee JM; Otto PM
Radiology; 2023 Jul; 308(1):e222612. PubMed ID: 37462494
[TBL] [Abstract][Full Text] [Related]
6. Gadobutrol-Enhanced Magnetic Resonance Imaging of the Breast in the Preoperative Setting: Results of 2 Prospective International Multicenter Phase III Studies.
Sardanelli F; Newstead GM; Putz B; Jirakova Trnkova Z; Trimboli RM; Abe H; Haverstock D; Rosenberg M
Invest Radiol; 2016 Jul; 51(7):454-61. PubMed ID: 26840494
[TBL] [Abstract][Full Text] [Related]
7. The comparison of high-resolution diffusion weighted imaging (DWI) with high-resolution contrast-enhanced MRI in the evaluation of breast cancers.
Kishimoto AO; Kataoka M; Iima M; Honda M; Miyake KK; Ohashi A; Ota R; Kataoka T; Sakurai T; Toi M; Togashi K
Magn Reson Imaging; 2020 Sep; 71():161-169. PubMed ID: 32320723
[TBL] [Abstract][Full Text] [Related]
8. Limited role of DWI with apparent diffusion coefficient mapping in breast lesions presenting as non-mass enhancement on dynamic contrast-enhanced MRI.
Avendano D; Marino MA; Leithner D; Thakur S; Bernard-Davila B; Martinez DF; Helbich TH; Morris EA; Jochelson MS; Baltzer PAT; Clauser P; Kapetas P; Pinker K
Breast Cancer Res; 2019 Dec; 21(1):136. PubMed ID: 31801635
[TBL] [Abstract][Full Text] [Related]
9. Dynamic contrast-enhanced and ultra-high-resolution breast MRI at 7.0 Tesla.
Stehouwer BL; Klomp DW; van den Bosch MA; Korteweg MA; Gilhuijs KG; Witkamp AJ; van Diest PJ; Houwert KA; van der Kemp WJ; Luijten PR; Mali WP; Veldhuis WB
Eur Radiol; 2013 Nov; 23(11):2961-8. PubMed ID: 23982289
[TBL] [Abstract][Full Text] [Related]
10. Phase 3 efficacy and safety trial of gadobutrol, a 1.0 molar macrocyclic MR imaging contrast agent, in patients referred for contrast-enhanced MR imaging of the central nervous system.
Gutierrez JE; Rosenberg M; Duhaney M; Simon JA; Brueggenwerth G; Agris JM; Knopp EA
J Magn Reson Imaging; 2015 Mar; 41(3):788-96. PubMed ID: 24578298
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine-enhanced magnetic resonance imaging in five hundred seventy-two patients with known or suspected liver lesions: results of a multicenter, double-blind, interindividual, randomized clinical phase-III trial.
Hammerstingl R; Adam G; Ayuso JR; Van Beers B; Belfiore G; Bellin MF; Bongartz G; Ernst O; Frericks B; Giuseppetti G; Heinz-Peer G; Laghi A; Martin J; Pering C; Reimer P; Richter GM; Roemer FW; Schäfer FK; Vilgrain V; Vogl TJ; Weishaupt D; Wall A; Zech CJ; Tombach B
Invest Radiol; 2009 Mar; 44(3):168-76. PubMed ID: 19169143
[TBL] [Abstract][Full Text] [Related]
12. Contrast-enhanced 3.0-T breast MRI for characterization of breast lesions: increased specificity by using vascular maps.
Schmitz AC; Peters NH; Veldhuis WB; Gallardo AM; van Diest PJ; Stapper G; van Hillegersberg R; Mali WP; van den Bosch MA
Eur Radiol; 2008 Feb; 18(2):355-64. PubMed ID: 17882425
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MRI of breast lesions: a prospective clinical investigation of the quantitative imaging biomarker characteristics of reproducibility, repeatability, and diagnostic accuracy.
Spick C; Bickel H; Pinker K; Bernathova M; Kapetas P; Woitek R; Clauser P; Polanec SH; Rudas M; Bartsch R; Helbich TH; Baltzer PA
NMR Biomed; 2016 Oct; 29(10):1445-53. PubMed ID: 27553252
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases.
Katakami N; Inaba Y; Sugata S; Tsurusaki M; Itoh T; Machida T; Tanaka H; Nakayama T; Morikawa T; Breuer J; Aitoku Y
Invest Radiol; 2011 Jul; 46(7):411-8. PubMed ID: 21467949
[TBL] [Abstract][Full Text] [Related]
15. Breast lesion detection and characterization with contrast-enhanced magnetic resonance imaging: Prospective randomized intraindividual comparison of gadoterate meglumine (0.15 mmol/kg) and gadobenate dimeglumine (0.075 mmol/kg) at 3T.
Clauser P; Helbich TH; Kapetas P; Pinker K; Bernathova M; Woitek R; Kaneider A; Baltzer PAT
J Magn Reson Imaging; 2019 Apr; 49(4):1157-1165. PubMed ID: 30552829
[TBL] [Abstract][Full Text] [Related]
16. Cerebral neoplastic enhancing lesions: multicenter, randomized, crossover intraindividual comparison between gadobutrol (1.0M) and gadoterate meglumine (0.5M) at 0.1 mmol Gd/kg body weight in a clinical setting.
Anzalone N; Scarabino T; Venturi C; Cristaudo C; Tartaro A; Scotti G; Zimatore D; Floris R; Carriero A; Longo M; Cirillo M; Cova MA; Gatti S; Voth M; Colosimo C
Eur J Radiol; 2013 Jan; 82(1):139-45. PubMed ID: 21890295
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): A retrospective comparison in 66 breast lesions.
Li L; Roth R; Germaine P; Ren S; Lee M; Hunter K; Tinney E; Liao L
Diagn Interv Imaging; 2017 Feb; 98(2):113-123. PubMed ID: 27687829
[TBL] [Abstract][Full Text] [Related]
18. Gadobutrol for magnetic resonance imaging of chronic myocardial infarction: intraindividual comparison with gadopentetate dimeglumine.
Durmus T; Schilling R; Doeblin P; Huppertz A; Hamm B; Taupitz M; Wagner M
Invest Radiol; 2012 Mar; 47(3):183-8. PubMed ID: 22183078
[TBL] [Abstract][Full Text] [Related]
19. Gadobutrol in the central nervous system at three doses: results from a phase II, randomized, multicenter trial.
Breuer J; Gutierrez J; Latchaw R; Lehr R; Sorensen AG
J Magn Reson Imaging; 2014 Feb; 39(2):410-8. PubMed ID: 23681501
[TBL] [Abstract][Full Text] [Related]
20. Lesion type and reader experience affect the diagnostic accuracy of breast MRI: a multiple reader ROC study.
Baltzer PAT; Kaiser WA; Dietzel M
Eur J Radiol; 2015 Jan; 84(1):86-91. PubMed ID: 25466772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
